USPTO serial 78040636
BITE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 14, 2006
- Examiner
- BLANDU, FLORENTINA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with BITE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
81477 Munchen, DE
MUNICH, DE
81477 Munchen, DE
81477 Munchen, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elsa D. Lemoine
Elsa D. Lemoine Amgen Inc.One Amgen Center DriveTrademark Operations - MS-28-5AThousand Oaks, CA 91320-1799Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Medicaments, namely, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host diseases, transplant rejection, coronary heart diseases, and minimal residual diseases, in the form of intravenous, sub-cutaneous, intra-peritoneal, intra-muscular and aerosol therapies ] | SECTION 8 - CANCELLED | — |
| 035 | [ Human and veterinary services, namely, licensing of medicaments, namely, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases, and minimal residual diseases; licensing of technology for the identification of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases, and minimal residual diseases, and for the identification of expressed genes, particularly of abnormal expressed genes, for the analysis and identification of the gene expression pattern and eukaryotic cells, particularly of single cells and cell culture lines, particularly of mammalian and human cells, particularly of cells of microscopic small biopsies of animal and human tissues, of cells out of tissue samples prepared with laser, of cells isolated with FACS or with receptor to ligand binding, of chemical fixed tissue, of micrometastatic cells, of bone marrow cells, of samples of body fluids, particularly from liquor, blood, lymph, urine or bowel movement, of stem cells, cloned single cells or differentiated stages from specific cells ] | SECTION 8 - CANCELLED | — |
| 042 | Medical services; laboratory research in the field of polypeptides, particularly antibodies and antibody derivatives; human and veterinary services, namely, product development, in the field of medicaments, namely, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases and minimal residual diseases; product development, in the field of diagnostic and testing apparatus and instruments for the identification of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host diseases, transplant rejection, coronary heart diseases, and minimal residual diseases, and for the identification of expressed genes, particularly of abnormal expressed genes, for the analysis and identification of the gene expression pattern and eukaryotic cells, particularly of single cells and cell culture lines, particularly of mammalian and human cells, particularly of cells of microscopic small biopsies of animal and human tissues, of cells out of tissue samples prepared with laser, of cells isolated with FACS or with receptor to ligand binding, of chemical fixed tissue, of micrometastatic cells, of bone marrow cells, of samples of body fluids, particularly from liquor, blood, lymph, urine or bowel movement, of stem cells, cloned single cells or differentiated stages from specific cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MICROMET AG
- Other trademarks owned by AMGEN RESEARCH (MUNICH) GMBH
- Other trademarks owned by MICROMET AG
- Other trademarks owned by MICROMET AG
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named BITE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 8, 2026 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| May 8, 2026 | RNL2 | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| May 8, 2026 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| May 7, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 4, 2026 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Mar 14, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 29, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 29, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 29, 2022 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Apr 29, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 29, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 29, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 29, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 7, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 7, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 2, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 28, 2016 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Jun 28, 2016 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jun 28, 2016 | 9G8P | REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8 | — |
| Jun 28, 2016 | 8PRT | REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED | — |
| Jun 28, 2016 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 8, 2016 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Mar 23, 2016 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 14, 2015 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Apr 2, 2012 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Apr 1, 2012 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Mar 31, 2012 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 1, 2012 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 18, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 14, 2006 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 1, 2006 | REGV | LAW OFFICE REGISTRATION REVIEW COMPLETED | — |
| Feb 1, 2006 | ALIE | ASSIGNED TO LIE | — |
| Jan 17, 2006 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Dec 27, 2005 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Dec 5, 2005 | PAPER RECEIVED | — | |
| Dec 2, 2005 | IUAF | USE AMENDMENT FILED | — |
| Jun 3, 2005 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 19, 2005 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 19, 2005 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 8, 2004 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 29, 2004 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 29, 2004 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 28, 2004 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 26, 2004 | CFIT | CASE FILE IN TICRS | — |
| May 19, 2004 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 19, 2004 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 2, 2003 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 29, 2003 | PAPER RECEIVED | — | |
| Sep 9, 2003 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 20, 2003 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 24, 2003 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 22, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 22, 2003 | PAPER RECEIVED | — | |
| Jan 6, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 21, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 21, 2002 | PAPER RECEIVED | — | |
| Jun 26, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 10, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 10, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Feb 14, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 5, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 4, 2002 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Nov 29, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 6, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 17, 2001 | DOCK | ASSIGNED TO EXAMINER | — |